(NASDAQ: CAI) Caris Life Sciences's forecast annual revenue growth rate of 16.24% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Caris Life Sciences's revenue in 2026 is $907,291,000.On average, 14 Wall Street analysts forecast CAI's revenue for 2026 to be $286,638,224,730, with the lowest CAI revenue forecast at $269,575,617,980, and the highest CAI revenue forecast at $299,924,217,395. On average, 14 Wall Street analysts forecast CAI's revenue for 2027 to be $344,022,405,815, with the lowest CAI revenue forecast at $305,012,469,905, and the highest CAI revenue forecast at $370,029,029,755.
In 2028, CAI is forecast to generate $403,102,671,070 in revenue, with the lowest revenue forecast at $335,541,984,965 and the highest revenue forecast at $458,790,767,985.